open access
Impact of Ga-PSMA PET/CT in the treatment of prostate cancer: Initial experience in Spain
open access
Abstract
Aim
To evaluate whether positron-emission tomography/computed tomography with 68Ga-PSMA (68Ga-PSMA PET/CT) influences the therapeutic management of patients with primary or recurrent prostate cancer (PCa).
Background
Although 68Ga-PSMA PET/CT is one of the best options for staging or restaging patients with PCa, its availability is still very limited in Spain. The present study reports the results of the first group of patients in Spain who underwent 68Ga-PSMA PET/CT imaging.
Materials and methods
All patients (n = 27) with a histological diagnosis of PCa who underwent 68Ga-PSMA PET/CT prior to the definitive treatment decision at the only centre with this technology in Spain during 2017–2018 were included. Two nuclear medicine physicians and a radiologist reviewed the imaging studies. The clinical impact was assessed from a theoretical perspective, based on the treatment that would have been applied if no data from the 68Ga-PSMA PET/CT were available.
Results
Most patients (n = 26; 96%) had persistent disease or biochemical recurrence after radical prostatectomy, radiotherapy, or combined treatment. One patient underwent 68Ga-PSMA PET/CT imaging to stage high-risk PCa. Overall, 68Ga-PSMA PET/CT was positive in 19 patients (70.4%). In 68.75% of these patients, none of the other imaging tests—MRI, CT, or bone scans—performed prior to the 68Ga-PSMA PET/CT were able to detect the presence of cancerous lesions. Overall, the findings of the 68Ga-PSMA PET/CT led to a modification of the therapeutic approach in 62.96% of the patients in the study.
Conclusions
68Ga-PSMA PET/CT alters the therapeutic approach in a substantial proportion of patients with PCa.
Abstract
Aim
To evaluate whether positron-emission tomography/computed tomography with 68Ga-PSMA (68Ga-PSMA PET/CT) influences the therapeutic management of patients with primary or recurrent prostate cancer (PCa).
Background
Although 68Ga-PSMA PET/CT is one of the best options for staging or restaging patients with PCa, its availability is still very limited in Spain. The present study reports the results of the first group of patients in Spain who underwent 68Ga-PSMA PET/CT imaging.
Materials and methods
All patients (n = 27) with a histological diagnosis of PCa who underwent 68Ga-PSMA PET/CT prior to the definitive treatment decision at the only centre with this technology in Spain during 2017–2018 were included. Two nuclear medicine physicians and a radiologist reviewed the imaging studies. The clinical impact was assessed from a theoretical perspective, based on the treatment that would have been applied if no data from the 68Ga-PSMA PET/CT were available.
Results
Most patients (n = 26; 96%) had persistent disease or biochemical recurrence after radical prostatectomy, radiotherapy, or combined treatment. One patient underwent 68Ga-PSMA PET/CT imaging to stage high-risk PCa. Overall, 68Ga-PSMA PET/CT was positive in 19 patients (70.4%). In 68.75% of these patients, none of the other imaging tests—MRI, CT, or bone scans—performed prior to the 68Ga-PSMA PET/CT were able to detect the presence of cancerous lesions. Overall, the findings of the 68Ga-PSMA PET/CT led to a modification of the therapeutic approach in 62.96% of the patients in the study.
Conclusions
68Ga-PSMA PET/CT alters the therapeutic approach in a substantial proportion of patients with PCa.
Keywords
Biochemical recurrence; Staging; PSMA; PET/CT; Prostate cancer
About this articleTitle
Impact of Ga-PSMA PET/CT in the treatment of prostate cancer: Initial experience in Spain
Journal
Reports of Practical Oncology and Radiotherapy
Issue
Pages
405-411
Published online
2020-05-01
DOI
10.1016/j.rpor.2020.03.024
Bibliographic record
Rep Pract Oncol Radiother 2020;25(3):405-411.
Keywords
Biochemical recurrence
Staging
PSMA
PET/CT
Prostate cancer
Authors
Felipe Couñago
Claudio Martínez-Ballesteros
Carlos Artigas
Ana Aurora Díaz-Gavela
Luis Leonardo Gómez
María Eugenia Lillo-García
José Reinaldo Chicharo
Manuel Recio
Antonio Maldonado
Israel J. Thuissard
Cristina Andreu-Vázquez
David Sanz-Rosa
Antonio José Conde-Moreno
Francisco José Marcos
Sofía Sánchez García
Juan Ignacio Martínez-Salamanca
Joaquin Carballido-Rodríguez
Javier Hornedo
Elia del Cerro